Merck (MRK) on Solana

Keytruda generated $31.7 billion in 2025 revenue — 55% of Merck's total pharmaceutical sales — and faces U.S. patent expiration beginning in 2028, putting the company under pressure to secure replacement revenue before biosimilar competition erodes that base. CEO Robert Davis has signaled ongoing deal activity following recent acquisitions of Verona Pharma, Cidara Therapeutics, and Terns Pharmaceuticals ($6.7 billion, March 2026), stating publicly, "And we're not done." Large pharma broadly faces a projected $400–500 billion patent-expiration gap over the next decade, making M&A the primary lever to maintain revenue.

Retail traders are debating two speculative biotech targets: Sellas Life Sciences (SLS), whose WT1-targeting immunotherapy Galinpepimut-S is completing a Phase 3 trial in acute myeloid leukemia with broad multi-cancer application potential, and MoonLake Immunotherapeutics (MLTX), whose lead drug Sonelokimab is on track for a BLA submission by September 30 for hidradenitis suppurativa. T. Rowe Price CIO David Giroux named MoonLake among seven likely acquisition candidates and anticipates 50–100% acquisition premiums for biotech targets; a prior nonbinding Merck offer above $3 billion for MoonLake was reported last year. SLS has gained 155% since the Terns deal announcement, while MLTX message volume surged 760% in a week, reflecting heightened retail speculation rather than confirmed deal activity.

Merck (MRK) closed at $123.54, down 1.22% on the day, even as the S&P 500 gained 0.42%. The divergence reflects a combination of elevated valuation and a steep projected earnings decline: full-year EPS is forecast at $5.17, a 42.43% drop year-over-year, against revenue growth of only 2.7% to an estimated $66.76 billion. The stock's forward P/E of 24.21 sits well above the Large Cap Pharmaceuticals industry average of 16.45, leaving little margin for error if earnings disappoint.

Analyst sentiment has edged lower, with consensus EPS estimates slipping 0.03% over the past month and a Zacks Rank of #3 (Hold) signaling a neutral outlook. The broader pharmaceutical sector is adding pressure: the Large Cap Pharmaceuticals industry ranks #178 out of all tracked industries, placing it in the bottom 28%. For Q3 2026, analysts expect EPS of $2.15, just 0.94% above the year-ago figure, offering limited near-term upside catalyst.

The FDA granted new approvals for KEYTRUDA-based regimens in two cancer indications — triple-negative breast cancer and muscle-invasive bladder cancer — while regulatory authorities in the EU cleared additional KEYTRUDA combinations in early-stage oncology settings, extending pembrolizumab's reach across multiple tumor types.

In a separate development, Merck reported positive Phase 3 results for tulisokibart, an anti-TL1A monoclonal antibody being evaluated in moderate-to-severe ulcerative colitis. The data position the therapy for regulatory filings, broadening Merck's pipeline beyond oncology into immunology.

The bipartisan House Select Committee on China, led by Rep. John Moolenaar, has opened a national security investigation into Merck's clinical trial operations in China, giving the company until July 17 to provide due diligence and data protection details. According to the committee, Merck has sponsored or collaborated on 224 clinical studies in China since 2005, including more than 31 trials at sites in Xinjiang — a region tied to Beijing's alleged human rights abuses against Uyghurs — and 40 trials at military-affiliated hospitals.

The investigation raises two distinct concerns for Merck. First, the Xinjiang trials face scrutiny over documented lapses in informed consent by Chinese researchers, exposing the company to reputational and legal risk. Second, the committee warns that conducting research at PRC military hospitals puts Merck's cutting-edge biotech intellectual property at risk of theft. Proposed legislation, the Biotech Investment National Security Act, would mandate strict national security reviews of outbound biotech deals with China, potentially constraining where major pharmaceutical companies like Merck can run trials or form partnerships going forward.

Merck (MRK) has delivered a sharp run-up, gaining 13% over the past seven days and roughly 21% year-to-date, with shares trading around $128.66. The multi-month rally reflects investor confidence in Merck's oncology pipeline — which includes 20-plus potential growth drivers — alongside recent acquisitions and licensing activity, while the longer-term one-year return sits at 68%.

Valuation readings, however, send conflicting signals. A discounted cash-flow model pegs Merck's intrinsic value at roughly $228 per share, implying the stock trades at a steep 44% discount and looks materially undervalued. P/E analysis tells a different story: Merck's current multiple of about 35.6x sits well above the pharma industry average of 14.7x and its peer group average of around 26.6x, leaving the stock appearing stretched on an earnings basis. A proprietary fair-ratio model sets fair value closer to $134, and bull- and bear-case fair value estimates range from roughly $102 to $130 — bracketing the current price tightly. Key risk factors include KEYTRUDA patent exclusivity timelines, GARDASIL demand headwinds in China, and ongoing generic and biosimilar competition.

The European Commission has approved Merck's KEYTRUDA (pembrolizumab) in combination with Padcev (enfortumab vedotin-ejfv) as a perioperative regimen — given as neoadjuvant treatment before surgery and continued as adjuvant treatment after radical cystectomy — for adults with resectable muscle-invasive bladder cancer who are ineligible for cisplatin-containing chemotherapy. According to Merck, the combination is the first PD-1 inhibitor plus antibody-drug conjugate regimen cleared for this patient population in the European Union, following a positive CHMP opinion issued in May 2026.

The approval is based on the Phase 3 KEYNOTE-905 trial, which Merck reported showed the perioperative combination reduced the risk of event-free survival events by 60% and the risk of death by 50% versus surgery alone, alongside a markedly higher pathologic complete response rate (57.1% versus 8.6%). The decision expands the European footprint of Keytruda, Merck & Co.'s flagship immuno-oncology franchise, into an earlier-stage bladder cancer setting.